State of Tennessee Treasury Department Boosts Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

State of Tennessee Treasury Department boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) by 17.9% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 3,657 shares of the specialty pharmaceutical company’s stock after buying an additional 554 shares during the period. State of Tennessee Treasury Department’s holdings in ANI Pharmaceuticals were worth $103,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ANIP. Rubric Capital Management LP purchased a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $14,172,000. Emerald Advisers LLC raised its holdings in ANI Pharmaceuticals by 326.8% in the first quarter. Emerald Advisers LLC now owns 354,045 shares of the specialty pharmaceutical company’s stock valued at $9,952,000 after buying an additional 271,101 shares during the period. Emerald Mutual Fund Advisers Trust raised its holdings in ANI Pharmaceuticals by 234.7% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 299,493 shares of the specialty pharmaceutical company’s stock valued at $8,419,000 after buying an additional 210,002 shares during the period. Thompson Siegel & Walmsley LLC raised its stake in shares of ANI Pharmaceuticals by 51.7% during the first quarter. Thompson Siegel & Walmsley LLC now owns 424,087 shares of the specialty pharmaceutical company’s stock valued at $11,921,000 after purchasing an additional 144,533 shares during the period. Finally, Summit Partners Public Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $4,466,000. Hedge funds and other institutional investors own 56.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ANIP shares. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. TheStreet upgraded shares of ANI Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, August 17th. Finally, Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $47.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $59.00.

ANI Pharmaceuticals Stock Down 4.5 %

ANIP stock opened at $34.94 on Wednesday. ANI Pharmaceuticals, Inc. has a twelve month low of $22.31 and a twelve month high of $60.23. The company has a current ratio of 3.35, a quick ratio of 2.39 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $609.25 million, a P/E ratio of -8.50 and a beta of 1.00. The firm has a 50 day simple moving average of $33.53 and a 200-day simple moving average of $31.53.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last released its quarterly earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). ANI Pharmaceuticals had a positive return on equity of 3.68% and a negative net margin of 25.32%. The company had revenue of $73.86 million for the quarter, compared to analyst estimates of $71.00 million. During the same period in the previous year, the business posted $0.49 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 0.67 earnings per share for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP James G. Marken sold 5,172 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $37.79, for a total transaction of $195,449.88. Following the completion of the sale, the senior vice president now owns 117,642 shares of the company’s stock, valued at $4,445,691.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other ANI Pharmaceuticals news, SVP James G. Marken sold 12,894 shares of ANI Pharmaceuticals stock in a transaction on Friday, August 12th. The shares were sold at an average price of $37.04, for a total value of $477,593.76. Following the completion of the transaction, the senior vice president now owns 122,814 shares of the company’s stock, valued at $4,549,030.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP James G. Marken sold 5,172 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 15th. The stock was sold at an average price of $37.79, for a total transaction of $195,449.88. Following the completion of the transaction, the senior vice president now directly owns 117,642 shares of the company’s stock, valued at approximately $4,445,691.18. The disclosure for this sale can be found here. Corporate insiders own 27.20% of the company’s stock.

ANI Pharmaceuticals Company Profile

(Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

See Also

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.